BICARA THERAPEUTICS INC (BCAX) Fundamental Analysis & Valuation

NASDAQ:BCAX • US0554771032

Current stock price

21.67 USD
+0.09 (+0.42%)
At close:
21.67 USD
0 (0%)
After Hours:

This BCAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. BCAX Profitability Analysis

1.1 Basic Checks

  • In the past year BCAX has reported negative net income.
  • In the past year BCAX has reported a negative cash flow from operations.
BCAX Yearly Net Income VS EBIT VS OCF VS FCFBCAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • BCAX has a Return On Assets of -32.01%. This is in the better half of the industry: BCAX outperforms 61.55% of its industry peers.
  • BCAX has a Return On Equity of -34.36%. This is in the better half of the industry: BCAX outperforms 70.68% of its industry peers.
Industry RankSector Rank
ROA -32.01%
ROE -34.36%
ROIC N/A
ROA(3y)-22.52%
ROA(5y)N/A
ROE(3y)-23.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCAX Yearly ROA, ROE, ROICBCAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • BCAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAX Yearly Profit, Operating, Gross MarginsBCAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BCAX Health Analysis

2.1 Basic Checks

  • BCAX has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for BCAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BCAX Yearly Shares OutstandingBCAX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 10M 20M 30M 40M 50M
BCAX Yearly Total Debt VS Total AssetsBCAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • BCAX has an Altman-Z score of 27.43. This indicates that BCAX is financially healthy and has little risk of bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 27.43, BCAX belongs to the top of the industry, outperforming 91.26% of the companies in the same industry.
  • BCAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.43
ROIC/WACCN/A
WACCN/A
BCAX Yearly LT Debt VS Equity VS FCFBCAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 14.58 indicates that BCAX has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 14.58, BCAX belongs to the best of the industry, outperforming 90.49% of the companies in the same industry.
  • A Quick Ratio of 14.58 indicates that BCAX has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 14.58, BCAX belongs to the best of the industry, outperforming 90.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.58
Quick Ratio 14.58
BCAX Yearly Current Assets VS Current LiabilitesBCAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BCAX Growth Analysis

3.1 Past

  • BCAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.64%, which is quite impressive.
EPS 1Y (TTM)37.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • BCAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.21% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.1%
EPS Next 2Y-9.07%
EPS Next 3Y-6.62%
EPS Next 5Y12.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCAX Yearly Revenue VS EstimatesBCAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
BCAX Yearly EPS VS EstimatesBCAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. BCAX Valuation Analysis

4.1 Price/Earnings Ratio

  • BCAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BCAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAX Price Earnings VS Forward Price EarningsBCAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAX Per share dataBCAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • BCAX's earnings are expected to decrease with -6.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.07%
EPS Next 3Y-6.62%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCAX Dividend Analysis

5.1 Amount

  • No dividends for BCAX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCAX Fundamentals: All Metrics, Ratios and Statistics

BICARA THERAPEUTICS INC

NASDAQ:BCAX (5/1/2026, 8:11:03 PM)

After market: 21.67 0 (0%)

21.67

+0.09 (+0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-30
Earnings (Next)05-19
Inst Owners83.49%
Inst Owner Change2.33%
Ins Owners1.26%
Ins Owner Change8.62%
Market Cap1.42B
Revenue(TTM)N/A
Net Income(TTM)-137.95M
Analysts82
Price Target31.11 (43.56%)
Short Float %16.79%
Short Ratio15.59
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.47%
Min EPS beat(2)-19.6%
Max EPS beat(2)0.66%
EPS beat(4)2
Avg EPS beat(4)-16.47%
Min EPS beat(4)-60.69%
Max EPS beat(4)13.77%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.19%
PT rev (3m)0.18%
EPS NQ rev (1m)6.69%
EPS NQ rev (3m)6.69%
EPS NY rev (1m)12.18%
EPS NY rev (3m)11.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.53
P/tB 3.53
EV/EBITDA N/A
EPS(TTM)-2.53
EYN/A
EPS(NY)-2.71
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS0
BVpS6.13
TBVpS6.13
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -32.01%
ROE -34.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.52%
ROA(5y)N/A
ROE(3y)-23.99%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 266.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.58
Quick Ratio 14.58
Altman-Z 27.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1159.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.36%
EPS Next Y-7.1%
EPS Next 2Y-9.07%
EPS Next 3Y-6.62%
EPS Next 5Y12.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-88.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.99%
EBIT Next 3Y-11.77%
EBIT Next 5YN/A
FCF growth 1Y-43.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.92%
OCF growth 3YN/A
OCF growth 5YN/A

BICARA THERAPEUTICS INC / BCAX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BICARA THERAPEUTICS INC (BCAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BCAX.


What is the valuation status of BICARA THERAPEUTICS INC (BCAX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BICARA THERAPEUTICS INC (BCAX). This can be considered as Overvalued.


Can you provide the profitability details for BICARA THERAPEUTICS INC?

BICARA THERAPEUTICS INC (BCAX) has a profitability rating of 1 / 10.


What is the financial health of BICARA THERAPEUTICS INC (BCAX) stock?

The financial health rating of BICARA THERAPEUTICS INC (BCAX) is 8 / 10.


What is the earnings growth outlook for BICARA THERAPEUTICS INC?

The Earnings per Share (EPS) of BICARA THERAPEUTICS INC (BCAX) is expected to decline by -7.1% in the next year.